February 4, 2022 -- DNA Script has inked a multimillion-dollar, multiyear contract with Wellcome Leap to accelerate RNA products, including mRNA vaccines, and advance RNA therapies. Under Wellcome Leap's RNA Response + Readiness (R3) program, DNA Script will develop a fully automated, deployable system to synthesize DNA templates for RNA production with a short turnaround time.
Wellcome Leap's R3 program, jointly funded by the Coalition for Epidemic Preparedness Innovations, seeks to increase the development and deployment of RNA-based biologic products as a standardized platform technology with reduced costs. In addition, the program aims to create a global network of state-of-the-art manufacturing facilities.
RNA development relies on the ability to rapidly design and produce genetic material. DNA Script's Syntax platform employs enzymatic DNA synthesis. R3's digital-sequence-to-RNA unique production technologies will help realize the ability to produce genetic material with exceptionally low error rates for plasmid DNA, according to the company.
DNA Script is a life sciences technology company developing a new, faster, more powerful and versatile way to design and manufacture nucleic acids.